Approval · Notice of Compliance 22031 · 2019
DEXILANT: Notice of Compliance 22031
Issued April 2, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22031
- Date
- April 2, 2019
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To expand the approved adult indications to include adolescents for healing of erosive esophagitis, maintenance of healed erosive esophagitis and symptomatic non-erosive gastroesophageal reflux disease
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DEXILANT | Not yet assigned | — |
Medicinal ingredients
- DEXLANSOPRAZOLE 30 MG per CAP
- DEXLANSOPRAZOLE 60 MG per CAP